EXECUTIVE SUMMARY

First half of 2026

Main figures €Mn

Op. Revenue	EBITDA	EBIT
344.2 (+9%)	121.2 (+85%)	103.2 (+103%)
Net profit	**Capex**	**Net cash**
84.4 (+113%)	30.4 (46%)	22.5

2026 operating revenue growth rate:
Increase by a low- to mid-single-digit percentage vs 2025

- ✓ Phoenix acquisition completed on April 1, 2026. Preliminary purchase price allocation resulted in a €62.4 Mn bargain purchase gain (badwill), recognized as non-recurring income in the consolidated income statement.

Operating revenue €Mn



Specialty pharma business €Mn

Total
€237.8m
+0.2%



€205.7 -1% Prescription products

€31.6 +10% Contrast agents

€0.5 -11% Other

Heparin franchise*

38% of operating revenue

€130.1m -4%

Enoxaparin sales €78.6m -2%

Bemiparin sales €46.7m -9%

- ✓ This performance was caused by a contraction in international sales, mainly due to overstocking by international partners.
- ✓ Despite YoY decline, strong international recovery in Q2 2026 (+53% YoY).
- ✓ 2026 outlook: low single-digit growth.

LMWH 2026 guidance improved

- ✓ Sales expected to decline by a mid single-digit percentage vs. 2025 (vs. a high-single-digit decline previously expected) due to lower orders from partners and pricing pressure

* LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins

Other prescription-based pharmaceutical products

Neparvis® €28.2m +2%

Okedi® €34.0m +27%

- ✓ Risperidone ISM®, a LAI of risperidone for schizophrenia.
- ✓ Marketed in Europe, Australia & Taiwan.

CDMO(1) business €Mn

Total
€106.3m
+38%

(*) "Other operating income" includes service activities that are not material to the Group.
(1)Contract Development and Manufacturing Organisation
To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 32-36) of the press release on the financial results for the first half of 2026. Said document is available on ROVI's website and may be accessed on the following link https://www.rovi.es/en/shareholders-investors/financial-business-information

Gross profit €Mn



SG&A expenses €Mn



EBITDA €Mn



R&D expenses €Mn €33.3 +98%

Product	Potential Indication	Current Situation	Key Milestones
Risperidone ISM®, monthly	**Schizophrenia**	Approved	Marketed in Europe, and in Australia & Taiwan
Letrozole ISM®, annual	**Breast Cancer**	Clinical development on hold	Phase I: Superior oestrogen suppression vs Femara®
Letrozole SIE(1), quarterly	**Breast Cancer**	Completion of phase I	Phase I: positive readout confirms superior estrogen suppression vs Femara® and allows progression to phase III clinical trial
Risperidone ISM®, quarterly	**Schizophrenia**	Completion of phase I	Phase I: positive readout allows progression to phase III clinical trial

Concentrated on improving posology for already approved compounds, which benefits risk / reward profile
Multiple FDA / GMP approved facilities to support the platform

Net profit €Mn



Closing remarks

- ✓ Strong momentum in CDMO business: consistent and focused execution
- ✓ Value creation from the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA)
- ✓ Vertical integration of the heparin division to enhance cost efficiency and improve competitiveness
- ✓ Sustained growth of the specialty pharmaceutical business, driven by Okedi®
- ✓ Strong R&D investment, with two clinical trials ongoing

(1) Superior Inhibition of Estrogen; (2) calculated excluding badwill in H1 2026 and R&D expenses in H1 2025 and in H1 2026.
To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 32-36) of the press release on the financial results for the first half of 2026. Said document is available on ROVI's website and may be accessed on the following link https://www.rovi.es/en/shareholders-investors/financial-business-information